Vibeke Krüse

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Max Schreuer, Yanina Jansen, Simon Planken et al. · The Lancet Oncology · 2017 · 179 citations

Single Arm, Advanced Brafv600-mutant Melanoma, Medicine +9

Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours

Christophe Van de Wiele, Vibeke Krüse, Peter Smeets et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2012 · 156 citations

Tumor Biology, Pancreatic Cancer, Metabolic Tumour Volume +11

Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Mathieu Spaas, Nora Sundahl, Vibeke Krüse et al. · JAMA Oncology · 2023 · 85 citations · Full text

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Yanina Jansen, Vibeke Krüse, Jurgen Corthals et al. · Cancer Immunology Immunotherapy · 2020 · 70 citations · Full text

Melanoma, Immunology, Therapeutic Vaccine +7

Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review

Marlies De Bock, Eva Hulstaert, Vibeke Krüse et al. · Case Reports in Dermatology · 2018 · 67 citations · Full text